The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Khokhlov A.L.

Yaroslavl State Medical University

Lileeva E.G.

Yaroslavl State Medical University

Rybachkova Yu.V.

Yaroslavl State Medical University

Petrova Ch.A.

Bashkir State Medical University

Oko E.F.

LLC «Doctor»

Arseenkova O.Yu.

Semashko National Research Institute of Public Health

Kiselev A.V.

Yaroslavl State Medical University

Mixed anxiety-depressive disorder in the early period of ischemic stroke and its treatment with ampakines

Authors:

Khokhlov A.L., Lileeva E.G., Rybachkova Yu.V., Petrova Ch.A., Oko E.F., Arseenkova O.Yu., Kiselev A.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12): 82‑87

DOI: 10.17116/jnevro202512512182

Read: 677 times

Buy for 300₽
Contact the author
Table of contents

MIXED ANXIETY-DEPRESSIVE DISORDER IN THE EARLY PERIOD OF ISCHEMIC STROKE AND ITS TREATMENT WITH AMPAKINES
MIXED ANXIETY-DEPRESSIVE DISORDER IN THE EARLY PERIOD OF ISCHEMIC STROKE AND ITS TREATMENT WITH AMPAKINES

To cite this article:

Khokhlov AL, Lileeva EG, Rybachkova YuV, Petrova ChA, Oko EF, Arseenkova OYu, Kiselev AV. Mixed anxiety-depressive disorder in the early period of ischemic stroke and its treatment with ampakines. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12):82‑87. (In Russ.)
https://doi.org/10.17116/jnevro202512512182

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Cere­brolysin with repe­rfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):84-98
Prediction of mortality in severe ischemic stroke during COVID-19 in patients with multiorgan dysfunction. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):120-127
A clinical case of treating a patient with severe ischemic stroke and cancer. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):114-117
Early anti­thrombotic protection of the brain in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):5-10
Resu­lts of the implementation of repe­rfusion technologies in ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):32-39
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Comparison of fluoroscopy and intracardiac echo­cardiography for control of endo­vascular closure of patent fora­men ovale. Russian Cardiology Bulletin. 2025;(1):64-69
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98
Abstract:

OBJECTIVE

Study of the efficacy of ampakins (Ampasse) in patients with anxiety and depressive disorders in the early recovery period of ischemic stroke (IS).

MATERIAL AND METHODS

The study included 203 patients with IS in the early recovery period who underwent rehabilitation measures at the Doctor Clinic medical facility (Tuimazy, Republic of Bashkortostan) in the period from January 2023 to August 2025. The study included patients with a history of IS no later than 3—6 months before the start date of the study, with signs of anxiety and depression of varying severity, who scored at least 8 points but no higher than 10 (the level of subclinically expressed symptoms) on the hospital anxiety and depression scale (HADS), as well as those who scored the required number of points on The Montreal Cognitive Function Assessment Scale (MoCA) (at least 10 points). The patients who met the inclusion criteria were randomly assigned to two groups: the experimental group and the control group. In the experimental group, 102 patients received Ampasse therapy in addition to standard therapy. The average age of these patients was 63±8.9 years, 48 of whom were women and 54 were men. In the control group, 101 patients received only basic therapy. The average age of the patients was 66±8.1 years), there were 45 women and 56 men. Throughout the study, the Beck anxiety, Beck depression, HADS, and the Spielberger-Khanin anxiety scales were also used.

RESULTS

The dynamics of improvement on all psychometric scales in the experimental group was statistically and clinically more pronounced than in the control group, which received only standard treatment.

CONCLUSION

The results of this study demonstrated the positive effect of Ampasse on reducing the symptoms of anxiety and depression in patients after undergoing AI in the early recovery period.

Keywords:

ischemic stroke
psychoemotional disorders
AMPA receptor
calcium hydroxynicotinoyl glutamate
post-stroke depression
post-stroke anxiety

Authors:

Khokhlov A.L.

Yaroslavl State Medical University

Lileeva E.G.

Yaroslavl State Medical University

Rybachkova Yu.V.

Yaroslavl State Medical University

Petrova Ch.A.

Bashkir State Medical University

Oko E.F.

LLC «Doctor»

Arseenkova O.Yu.

Semashko National Research Institute of Public Health

Kiselev A.V.

Yaroslavl State Medical University

Received:

20.11.2025

Accepted:

24.11.2025

Close metadata

References:

  1. Arkhincheeva NC, Balkhaev IM, Shadapova AH. Psychoemotional disorders in stroke patients and their modern pharmacotherapy. Bulletin of the Buryat State University. Medicine and Pharmacy. 2024;(1):3-12. (In Russ.).
  2. Mikhailov VA, Lukina LV, Safonova NYu. The effectiveness of neurotropic therapy in the treatment of nonpsychotic mental disorders in patients who have suffered a cerebral stroke. Review of Psychiatry and Medical Psychology named after V.M. Bekhterev. 2021;55(2):37-44. (In Russ.). https://doi.org/10.31363/2313-7053-2021-55-2-37-44
  3. Gusev EI, Gekht AB, Bogolepova AN, et al. Features of depressive syndrome in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2001;3:28-31. (In Russ.).
  4. Shi Y, Yang D, Zeng Y, et al. Risk factors for post-stroke depression: A Meta-analysis. Front Aging Neurosci. 2017;9:218. 
  5. Mikhailov VA, Druzhinin AK, Shova NI. Affective post-stroke disorders: pathogenesis, diagnosis, treatment. Review of Psychiatry and Medical Psychology named after V.M. Bekhterev. 2018;(1):115-119. (In Russ.).
  6. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9(8):1017-1025. https://doi.org/10.1111/ijs.12357
  7. Maksimova MYu, Khokhlova TYu, Suanova ET. Post-stroke depression as a common medical and social problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(3):96-103. (In Russ.).
  8. Williams L, Ghose SS, Swinde R. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. A J Psychiatry. 2004;61(6):1090-1095. https://doi.org/10.1176/appi.ajp.161.6.1090
  9. Charles E. Mortality and poststroke depression. A J Psychiatry. 2004; 161:1506. https://doi.org/10.1176/appi.ajp.161.8.1506
  10. Domashenko MA, Maksimova MYu, Orlov SV, et al. Post-stroke depression. Pharmateca. 2011;19:15-19. (In Russ.).
  11. Kasatkina MYu, Zhanin IS, Gulyaeva NV. Biomarkers of stroke and depression: are there specific markers of post-stroke depression? Neurochemistry. 2020;37(4):318-327. (In Russ.).
  12. Lincoln NB, Brinkmann N, Cunningham S, et al. Anxiety and depression after stroke: A 5 year follow-up. Disabil and Rehab. 2013;35:140-145. 
  13. Liguz-Lecznar M, Kossut M. Influence of inflammation on poststroke plasticity. Neural Plast. 2013;2013:258582. https://doi.org/10.1155/2013/258582
  14. Villa RF, Ferrari F, Moretti A. Post-stroke depression: Mechanisms and pharmacological treatment. Pharm Ther. 2018;184:131-144.  https://doi.org/10.1016/j.pharmthera.2017.11.005
  15. Mitre M, Mariga A, Chao MV. Neurotrophin signalling: novel insights into mechanisms and pathophysiology. Clin Sci. 2017;131(1):13-23.  https://doi.org/10.1042/CS20160044
  16. Zakharov VV. Glutamatergicheskaya terapiya v vosstanovitel’nom periode posle ishemicheskogo insul’ta. Effektivnaya farmakoterapiya. 2016;42:6-14. 
  17. Mazurov AA, Kombo DC, Akireddy S, et al. Novel nicotinic acetylcholine receptor agonists containing carbonyl moiety as a hydrogen bond acceptor. Bioorg Med Chem Lett. 2013;23(13):3927-3934. https://doi.org/10.1016/j.bmcl.2013.04.058
  18. Ward S, Bax B, Harries M. Challenges for and current status of research into positive modulators of AMPA receptors: a reviewa Br J Pharmacol. 2010; 160(2):181-190.  https://doi.org/10.1111/j.1476-5381.2010.00726.x
  19. Ahmed AH, Oswald RE. Piracetam Defines a New Binding Site for Allosteric Modulators of a-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic Acid (AMPA) Receptors. J Med Chem. 2010;53(5):2197-2203. https://doi.org/10.1021/jm901905j
  20. Khoodoruth MAS, Estudillo-Guerra MA, Pacheco-Barrios K, et al. Glutamatergic System in Depression and Its Role in Neuromodulatory Techniques Optimization. Front Psychiatry. 2022;13:886918. https://doi.org/10.3389/fpsyt.2022.886918
  21. Zhang X, Li J, Sha W, et al. Major Depressive Disorder — Cognitive and Neurobiological Mechanisms. Seoul: InTech; 2015:155. 
  22. Meng X, Li N, Guo DZ, et al. High plasma glutamate levels are associated with poor functional outcome in acute ischemic stroke. Cell Mol Neurobiol. 2015;35(2):159-165.  https://doi.org/10.1007/s10571-014-0107-0
  23. Inoshita M, Umehara H, Watanabe SY, et al. Elevated peripheral blood glutamate levels in major depressive disorder. Neuropsychiatr Dis Treat. 2018;14:945-953.  https://doi.org/10.2147/NDT.S159855
  24. Geng LY, Qian FY, Qian JF, et al. The combination of plasma glutamate and physical impairment after acute stroke as a potential indicator for the early-onset post-stroke depression. Psychosom Res. 2017;96:35-41.  https://doi.org/10.1016/j.jpsychores.2017.01.006
  25. Granzotto A, Canzoniero LMT, Sensi SL. A Neurotoxic Ménage-à-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade. Front Mol Neurosci. 2020;13:600089. https://doi.org/10.3389/fnmol.2020.600089
  26. Motin VG, Kiselev AV, Stovbun IS, et al. The calcium salt of N-(5-hydroxynicotinoyl)-L-glutamic acid changes the responses of pyramidal neurons in the CA1 region of the rat hippocampus during orthodromic stimulation. Bulletin of Experimental Biology and Medicine. 2018;165(1):27-30. (In Russ.). https://doi.org/10.1007/s10517-018-4091-0
  27. Kiselev AV, Vedenkin AS, Stovbun IS, et al. The calcium salt of N-(5-hydroxynicotinoyl)-L-glutamic acid weakens depressive-like behavior and Parkinsonian syndrome in an experiment on rodents. Bulletin of Experimental Biology and Medicine. 2019;168(1):48-51. (In Russ.). https://doi.org/10.1007/s10517-019-04643-5
  28. Kiselev AV, Vedenkin AS, Stovbun IS. The calcium salt of N-(5-hydroxynicotinoyl)-L-glutamic acid weakens depressive-like behavior and Parkinsonian syndrome in rodents. Bulletin of Experimental Biology and Medicine. 2019;168(7):56-59. (In Russ.).
  29. Kiselev AV, Vostrikova EV, Kalinina TS, et al. Randomized, double-blind, placebo-controlled study of the efficacy and safety of ampasse in the treatment of chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):21-25. (In Russ.). https://doi.org/10.17116/jnevro201911904121
  30. Skoromets AA, Kotov SV, Voronkov PB, et al. Efficacy and safety of ampasse therapy: results of a randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular accident. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5):26-32. (In Russ.). https://doi.org/10.17116/jnevro202112105126
  31. Zhitkova YuV, Gasparyan AA, Saikhunov MV, et al. An observational study of the efficacy and safety of Ampasse in patients with moderate cognitive impairment in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(10):75-80. (In Russ.). https://doi.org/10.17116/jnevro202312310175
  32. Belskaya GN, Sakharova EV, Kiryanova EA, et al. Possibilities of neuroprotective therapy in patients with chronic cerebral ischemia. Neurology and Neurosurgery. Eastern Europe. 2024;14(2):156-163. (In Russ.). https://doi.org/10.34883/PI.2024.14.2.046
  33. Chernykh IV, Shchulkin AV, Mylnikov PYu, et al. The effect of ampakin CX-516 on monoaminergic systems of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(5):68-74. (In Russ.).
  34. Kotov SV, Kiselev AV, Isakova EV, et al. The effect of the onset of cognitive rehabilitation after an ischemic stroke on the level of recovery. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8-2):77-83. (In Russ.). https://doi.org/10.17116/jnevro202312308277
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.